Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation

Transplantation

Volumn 62, Issue 10, 1996, Pages 1456-1462

  Bain, Vincent G ^a   Kneteman, Norman M ^b   Ma, Mang M ^b   Gutfreund, Klaus ^b   Shapiro, James A ^b   Fischer, Karl ^b   Tipples, Graham ^b   Lee, Helen ^b   Jewell, Laurence D ^b   Tyrrell, D Lorne ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 10544253075     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199611270-00013     Document Type: Article

References (23)

1. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619.
2. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. J Hepatol 1992; 14: 104.
3. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with hepatitis B surface antigen. N Engl J Med 1993; 329: 1842.
4. Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150.
5. UNOS update. J Hepatol 1995; 11: 37.
6. Hopf U, Neuhaus P, Lobeck H, et al. Follow-up of recurrent hepatitis B and delta infection in liver allograft recipients after treatment with recombinant interferon alpha. J Hepatol 1991; 13: 339.
7. Marcellin P, Samuel D, Areias J, et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplanation for hepatitis B-related endstage liver disease. Hepatology 1994; 19: 6.
8. Muller R, Gubernatis G, Farle M, et al. Liver transplantation in HBs carriers. Prevention of hepatitis B virus recurrence by passive immunization. J Hepatol 1991; 13: 90.
9. Samuel D, Bismuth A, Mathieu D, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337: 813.
10. Lake JR, Wright TL. Liver transplantation for patients with hepatitis B: what have we learned from our results? Hepatology 1991; 13: 796.
11. Perrillo RP, Mason AL. Hepatitis B and liver transplantation. N Engl J Med 1993; 329: 1885.
12. Wright T. The threat of hepatitis B virus recurrence: a sword of Damocles to the liver transplant recipient. Hepatology 1993; 18: 219.
13. Zetterman RK. Liver transplantation for hepatitis B: where do we go from here? Am J Gastroenterol 1995; 90: 2.
14. Tyrrell DLJ, Mitchell MC, De Man RA, et al. Phase II trial of lamivudine for chronic hepatitis B (abstract). Hepatology 1993; 18: 112A.
15. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657.
16. Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Molecular Biology 1975; 98: 503.
17. Tipples GA, Ma MM, Fischer KP, et al. Mutation in HBV RNA-dependant DNA polymerase confers resistence to lamivudine in vivo. Hepatology 1996; 24:714.
18. Mason A, Wick M, White H, Perrillo R. Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. Hepatology 1993; 18: 781.
19. Parkes WB, Cheung YC. Mitochondrial toxicity of antiviral nucleoside analogs. J NIH Research 1994; 6: 57.
20. McKenzie R, Fried MW, Sallie R. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333: 1099.
21. van Leeuwen R, Katlama C, Kitchen V, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic HIV infection: a phase I/II study. J Infect Dis 1995; 171: 1166.
22. Pluda JM, Cooley TP, Montaner JS, et al. A phase I/II study of 3TC (lamivudine) in patients with advanced HIV infection. J Infect Dis 1995; 171: 1438.
23. Hart GJ, Orr DC, Penn CR, et al. Effects of 3TC, 5′ triphosphate on HIV transcriptase and mammalian DNA polymerases, O, β, and γ. Antimicrob Agents Chemother 1992; 36: 1688.